Synthesis and SAR studies of 1,4-diazabicyclo[3.2.2]nonane phenyl carbamates - subtype selective, high affinity α7 nicotinic acetylcholine receptor agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 16, 2009, Pages 4747-4751

  O'Donnell, Christopher J ^a   Peng, Langu ^a   O'Neill, Brian T ^a   Arnold, Eric P ^a   Mather, Robert J ^a   Sands, Steven B ^a   Shrikhande, Alka ^a   Lebel, Lorraine A ^a   Spracklin, Douglas K ^a   Nedza, Frank M ^a  

^a PFIZER INC   (United States)

Author keywords

1,4 Diazabicyclo 3.2.2 nonane phenyl carbamate; Agonist; Alpha 7; nAChR; Nicotinic acetylcholine receptor; SAR

Indexed keywords

1,4 DIAZABICYCLO[3.2.2]NONANE (4 BROMO)PHENYLCARBAMATE; 1,4 DIAZABICYCLO[3.2.2]NONANE PHENYLCARBAMATE DERIVATIVE; BUNGAROTOXIN RECEPTOR; CARBAMIC ACID DERIVATIVE; NICOTINIC AGENT; NICOTINIC RECEPTOR ALPHA7 AGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; HUMAN; HUMAN CELL; NONHUMAN; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; CARBAMATES; CELL LINE; HUMANS; MALE; NICOTINIC AGONISTS; PHENYLCARBAMATES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67651177769     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.06.059     Document Type: Article

References (39)

1. Lyon E.R. Psychiat. Serv. 50 (1999) 1346
2. Simosky J.K., Stevens K.E., and Freedman R. Curr. Drug Targ.-CNS & Neurol. Dis. 1 (2002) 149
3. Leonard S., Gault J., Hopkins J., Logel J., Vianzon R., Short M., Drebing C., Berger R., Venn D., Sirota P., Zerbe G., Olincy A., Ross R.G., Adler L.E., and Freedman R. Arch. Gen. Psychiat. 59 (2002) 1085
4. Lightfoot A.P., Kew J.N.C., and Skidmore J. Prog. Med. Chem. 46 (2008) 131
5. Olincy A., and Stevens K.E. Biochem. Pharmacol. 74 (2007) 1192
6. Levin E.D., and Simon B.B. Psychopharmacology 138 (1998) 217
7. Wishka D.G., Walker D.P., Yates K.M., Reitz S.C., Jia S., Myers J.K., Olson K.L., Jacobsen E.J., Wolfe M.L., Groppi V.E., Hanchar A.J., Thornburgh B.A., Cortes-Burgos L.A., Wong E.H.F., Staton B.A., Raub T.J., Higdon N.R., Wall T.M., Hurst R.S., Walters R.R., Hoffmann W.E., Hajos M., Franklin S., Carey G., Gold L.H., Cook K.K., Sands S.B., Zhao S.X., Soglia J.R., Kalgutkar A.S., Arneric S.P., and Rogers B.N. J. Med. Chem. 49 (2006) 4425
8. Mullen G., Napier J., Balestra M., DeCory T., Hale G., Macor J., Mack R., Loch III J., Wu E., Kover A., Verhoest P., Sampognaro A., Phillips E., Zhu Y., Murray R., Griffith R., Blosser J., Gurley D., Machulskis A., Zongrone J., Rosen A., and Gordon J. J. Med. Chem. 43 (2000) 4045-4050
9. Tatsumi R., Seio K., Fujio M., Katayama J., Horikawa T., Hashimoto K., and Tanaka H. Bioorg. Med. Chem. Lett. 14 (2004) 3781
10. Macor, J. E.; Wu, E. WO97/30998, 1997.
11. Guendisch D., Andrae M., Munoz L., and Tilotta M.C. Bioorg. Med. Chem. 12 (2004) 4953
12. Walker D.P., Wishka D.G., Piotrowski D.W., Jia S., Reitz S.C., Yates K.M., Myers J.K., Vetman T.N., Margolis B.J., Jacobsen E.J., Acker B.A., Groppi V.E., Wolfe M.L., Thornburgh B.A., Tinholt P.M., Cortes-Burgos L.A., Walters R.R., Hester M.R., Seest E.P., Dolak L.A., Han F., Olson B.A., Fitzgerald L., Staton B.A., Raub T.J., Hajós M., Hoffmann W.E., Li K.S., Higdon N.R., Wall T.M., Hurst R.S., Wong E.H.F., and Rogers B.N. Bioorg. Med. Chem. 14 (2006) 8219
13. Rogers, B. N. Agonists of alpha 7 nAChRs for the Potential Treatment of Cognitive Deficits in Schizophrenia, Nicotinic Acetylcholine Receptors as Therapeutic Targets: Emerging Frontiers in Basic Research and Clinical Sciences; San Diego, CA, Oct. 31-Nov. 2, 2007.
14. i = 38.3 ± 3.6 nM (n = 27)
15. 2, 10 HEPES, pH 7.5) containing agonists or antagonists. Electrodes are filled with 3 M KCl. Holding potential (Vh) = -60 or -90 mV. Currents induced by the application of drugs were digitized by a Data Translation a/d board and analyzed with axodata software. All test compounds were tested at 32 μM and are compared to a test dose of nicotine at 50 μM. Data is reported as a % nicotine response with the nicotine response defined as 100%. For a comprehensive reference on the characterization of nicotinic receptors in oocytes see:. Chavez-Noriega L.E., Crona J.H., Washburn M.S., Urrutia A., Elliott K.J., and Johnson E.C. J. Pharmacol. Exp. Ther. 280 (1997) 346
16. McGuirk P.R., Jefson M.R., Mann D.D., Elliott N.C., Chang P., Cisek E.P., Cornell C.P., Gootz T.D., Haskell S.L., Hindahl M.S., LaFleur L.J., Rosenfeld M.J., Shryock T.R., Silvia A.M., and Weber F.H. J. Med. Chem. 35 (1992) 611
17. O'Donnell, C. J.; O'Neill, B. T. U.S.02/177591, 2002.
18. Concurrent to our work, scientists at Sanofi-Aventis also arrived at the same compound (5, SR 180711) and have reported detailed in vitro and in vivo data on this compound: (a) Gallet, T.; Jegham, S.; Lardenois, P.; Lochead, A.; Nedelec, A. WO00/58311, 2000.
19. Biton B., Bergis O.E., Galli F., Nedelec A., Lochead A.W., Jegham S., Godet D., Lanneau C., Santamaria R., Chesney F., Léonardon J., Granger P., Debono M.W., Bohme G.A., Sgard F., Besnard F., Graham D., Coste A., Oblin A., Curet O., Vigé X., Voltz C., Rouquier L., Souilhac J., Santucci V., Gueudet C., Francon D., Steinberg R., Griebel G., Oury-Donat F., George P., Avenet P., and Scatton B. Neuropsychopharmacology 32 (2007) 1
20. Pichat P., Bergis O.E., Terranova J.-P., Urani A., Duarte C., Santucci V., Gueudet C., Volts C., Steinberg R., Stemmelin J., Oury-Donat F., Avenet P., Griebel G., and Scatton B. Neuropsychopharmacology 32 (2007) 17
21. Barak S., Arad M., De Levie A., Black M.D., Griebel G., and Weiner I. Neuropsychopharmacology (2009) 1
22. Mikhlina E.E., and Rubtsov M.V. Zh. Org. Khim. 33 (1963) 2167
23. Rubtsov M.V., Mikhlina E.E., Vorob'eva V.Ya., and Yanina A.D. Zh. Org. Khim. 34 (1964) 2222
24. Ishiyama T., Murata M., and Miyaura N. J. Org. Chem. 60 (1995) 7508
25. For experimental details along with full characterization date see Ref. 12.
26. Mendoza J.S., Jagdmann G.E., and Gosnell P.A. Bioorg. Med. Chem. Lett. 5 (1995) 2211
27. 2).
28. Horenstein N.A., Leonik F.M., and Papke R.L. Mol. Pharmacol. 74 (2008) 1496
29. Rat brain homogenate binding assay was performed as previously described, see:. Lippiello P.M., and Fernandes K.G. Mol. Pharmacol. 29 (1986) 448
30. 50 = 1.65 ± 0.47 nM (n = 12)
31. Compound 24 was prepared by reacting 1,4-diazabicyclo[3.2.2]nonane with 4-bromophenylisocyanate in 14% yield.
32. Compound 25 was prepared by reacting 1,4-diazabicyclo[3.2.2]nonane with 2-(4-bromophenyl)acetyl chloride in 41% yield.
33. Compound 26 was prepared by reacting 1,4-diazabicyclo[3.2.2]nonane with phenylchlorothionocarbonate using the conditions to prepare 7 in 58% yield.
34. Compound 27 was prepared from benzylchloroformate using the conditions to prepare 7 in 15% yield.
35. Compound 28 was prepared by reacting 1,4-diazabicyclo[3.2.2]nonane with 4-bromophenylsulfonylchloride in 41% yield.
36. IMR32 cells binding assay was performed as previously described, see:. Donnelly-Roberts D.L., Puttfarcken P.S., Kuntzweiler T.A., Briggs C.A., Anderson D.J., Campbell J.E., Piattoni-Kaplan M., McKenna D.G., Wasicak J.T., Holladay M.W., Williams M., and Arneric S.P. J. Pharmacol. Exp. Ther. 285 (1998) 777
37. 50 = 15.6 ± 1.76 nM (n = 3)
38. The chloroformate used to prepare 7z was prepared in three-steps from 2-bromo-5-hydroxybenzaldehyde (Harmata, M.; Kahraman, M. J. Org. Chem. 1999, 64, 4949). 2-Bromo-5-hydroxybenzaldehyde was reacted with phenyl magnesium bromide in THF at rt to give 4-bromo-3-(hydroxy(phenyl)methyl)phenol in 88% yield. Swern oxidation provided (2-bromo-5-hydroxyphenyl)-(phenyl)methanone in 22% yield which was treated with phosgene to give the desired chloroformate.
39. Wong D.T., Robertson D.W., and Reid L.R. Eur. J. Pharmacol. 166 (1989) 107